Inhibrx Biosciences Inc.

NASDAQ: INBX · Real-Time Price · USD
12.90
-0.10 (-0.77%)
At close: Jun 05, 2025, 3:59 PM
12.89
-0.12%
After-hours: Jun 05, 2025, 04:04 PM EDT

Company Description

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.

Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma.

The company was incorporated in 2024 and is based in La Jolla, California.

Inhibrx Biosciences Inc.
Inhibrx Biosciences Inc. logo
Country United States
IPO Date Jun 4, 2024
Industry Biotechnology
Sector Healthcare
Employees 156
CEO Mark Paul Lappe

Contact Details

Address:
11025 North Torrey Pines Road
La Jolla, California
United States
Website https://inhibrx.com

Stock Details

Ticker Symbol INBX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001739614
CUSIP Number 45720L107
ISIN Number US45720L1070
Employer ID 82-4257312
SIC Code 2836

Key Executives

Name Position
Mark Paul Lappe Founder, Chief Executive Officer & Chairman
Kelly Devine Deck B.S., CPA, M.S. Executive Vice President, Chief Financial Officer & Treasurer
Bonne Adams M.B.A. Vice President of Operations
David J. Matly M.B.A. President and Chief Commercial & Business Development Officer
Dr. Ashraf Amanullah Ph.D. Executive Vice President & Chief Technical Operations Officer
Dr. Carlos Bais Ph.D. EVice President & Chief Scientific Officer
Dr. Josep Garcia Ph.D. Executive Vice President & Chief Clinical Development Officer
Leah Pollema J.D. Vice President, General Counsel & Corporate Secretary

Latest SEC Filings

Date Type Title
Jun 02, 2025 POS AM Filing
May 29, 2025 4 Filing
May 29, 2025 4 Filing
May 29, 2025 4 Filing
May 29, 2025 4 Filing
May 28, 2025 424B3 Filing
May 28, 2025 8-K Current Report
May 14, 2025 424B3 Filing
May 14, 2025 8-K Current Report
May 14, 2025 10-Q Quarterly Report